PCAS

Earnings Release • Jul 23, 2013

Longjumeau, July 23, 2013

(in thousands of euros)	H1-2012 published (including SBS)	H1-2012 restated (without SBS)	H1-2013	% change
Sales	89 361	87 506	89 044	+ 1,8%
including Pharmaceutical
Synthesis	55 364	55 360	58 077	+ 4,9%
including Fine Speciality Chemicals	33 997	32 146	30 967	- 3,7 %

(unaudited data)

For information, the sale of SBS was finalised on March 20, 2013. SBS was presented on a specific line as "Net Result on discontinued operation" as of December 31, 2012.

For the first half of 2013, the consolidated sales of the PCAS Group are up by 1.8% compared to the same period of the preceding year, without SBS.

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business has been continuing to develop in 2013 with growth of 4.9% relative to 2012.

Fine Specialty Chemicals

For the first half of 2013, Fine Specialty Chemicals are down (-3.7%) on 2012, affected by a sharp downturn in New Technologies business, while the Performance Chemicals business and, to a lesser extent, the Fragrance-Flavors-Cosmetics business have continued to grow.

The full six-monthly consolidated accounts will be examined by the Board of Directors on September 4, 2013.

About PCAS:

Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.